Detection of amyloid-β oligomers in human cerebrospinal fluid by flow cytometry and fluorescence resonance energy transfer

Journal of Alzheimer's Disease

Volumn 11, Issue 1, 2007, Pages 117-125

  Santos, Alexander Navarrete ^a   Torkler, Sandra ^a   Nowak, Denny ^a   Schlittig, Claudia ^a   Goerdes, Mirjam ^a   Lauber, Thomas ^a   Trischmann, Lothar ^a   Schaupp, Michael ^a   Penz, Monika ^b   Tiller, Friedrich Wilhelm ^b   Böhm, Gerald ^a  

^a ACGT ProGenomics AG   (Germany)

^b Labor Dr Tiller   (Germany)

Author keywords

Alzheimer's disease; Amyloid oligomers; Cerebrospinal fluid; Flow cytometry; Fluorescence resonance energy transfer

Indexed keywords

AMYLOID BETA PROTEIN; OLIGOMER;

ADOLESCENT; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FLOW CYTOMETRY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NEUROLOGIC DISEASE; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN STRUCTURE; RELIABILITY; REPRODUCIBILITY; SCHOOL CHILD;

EID: 33847730711     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2007-11114     Document Type: Article

References (24)

1. P.S. Aisen, The development of anti-amyloid therapy for Alzheimer's disease: from secretase modulators to polymerisation inhibitors, CNS Drugs 19 (2005), 989-996.
2. S. Barghorn, V. Nimmrich, A. Striebinger, C. Krantz, P. Keller, B. Janson, M. Bahr, M. Schmidt, R.S. Bitner, J. Harlan, E. Barlow, U. Ebert and H. Hillen, Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease, J Neurochem 31 (2005), 834-847.
3. A.L. Biere, B. Ostaszewski, E.R. Stimson, B.T. Hyman, J.E. Maggio and D.J. Selkoe, Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma, J Biol Chem 271 (1996), 32916-32922.
4. J.P. Cleary, D.M. Walsh, J.J. Hofmeister, G.M. Shankar, M.A. Kuskowski, D.J. Selkoe and K.H. Ashe, Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function, Nat Neurosci 1 (2005), 79-84.
5. K.N. Dahlgren, A.M. Manelli, W.B. Jr. Stine, L.K. Baker, G.A. Krafft and M.J. LaDu, Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability, J Biol Chem 277 (2002), 32046-32053.
6. M. Enya, M. Morishima-Kawashima, M. Yoshimura, Y. Shinkai, K. Kusui, K. Khan, D. Games, D. Schenk, S. Sugihara, H. Yamaguchi and Y. Ihara, Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging, Am J Pathol 154 (1999), 271-279.
7. A.L. Fitzpatrick, L.H. Kuller, O.L. Lopez, C.H. Kawas and W. Jagust, Survival following dementia onset: Alzheimer's disease and vascular dementia, J Neurol Sci 229-230 (2005), 43-49.
8. D.G. Georganopoulou, L. Chang, J.M. Nam, C.S. Thaxton, E.J. Mufson, W.L. Klein and C.A. Mirkin, Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease, Proc Natl Acad Sci USA 102 (2005), 2273-2276.
9. Y. Gong, L. Chang, K.L. Viola, P.N. Lacor, M.P. Lambert, C.E. Finch, G.A. Krafft and W.L. Klein, Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss, Proc Natl Acad Sci USA 100 (2003), 10417-10422.
10. E.A. Jares-Erijman and T.M. Jovin, FRET imaging, Nat Biotechnol 21 (2003), 1387-1395.
11. I. Klyubin, D.M. Walsh, C.A. Lemere, W.K. Cullen, G.M. Shankar, V. Betts, E.T. Spooner, L. Jiang, R. Anwyl, D.J. Selkoe and M.J. Rowan, Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo, Nat Med 6 (2005), 556-561.
12. Y.M. Kuo, M.R. Emmerling, C. Vigo-Pelfrey, T.C. Kasunic, J.B. Kirkpatrick, G.H. Murdoch, M.J. Ball and A.E. Roher, Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains, J Biol Chem 271 (1996), 4077-4081.
13. M.P. Lambert, A.K. Barlow, B.A. Chromy, C. Edwards, R. Freed, M. Liosatos, T.E. Morgan, I. Rozovsky, B. Trommer, K.L. Viola, P. Wals, C. Zhang, C.E. Finch, G.A. Krafft and W.L. Klein, Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous systemneurotoxins, Proc Natl Acad Sci USA 95 (1998), 6448-6453.
14. L.F Lue, Y.M. Kuo, A.E. Roher, L. Brachova, Y. Shen, L. Sue, T. Beach, J.H. Kurth, R.E. Rydel and J. Rogers, Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease, Am J Pathol 155 (1999), 853-862.
15. C.A. McLean, R.A. Cherny, F.W. Fraser, S.J. Fuller, M.J. Smith, K. Beyreuther, A.I. Bush and C.L. Masters, Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease, Ann Neurol 46 (1999), 860-866.
16. A. Olofsson, A.E. Sauer-Eriksson and A. Ohman, The solvent protection of alzheimer amyloid-beta-(1-42) fibrils as determined by solution NMR spectroscopy, J Biol Chem 281 (2006), 477-483.
17. M. Pitschke, R. Prior, M. Haupt and D. Riesner, Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by Fluorescence correlation spectroscopy, Nat Med 4 (1998), 832-834.
18. A.E. Roher, M.O. Chaney, Y.M. Kuo, S.D. Webster, W.B. Stine, L.J. Haverkamp, A.S. Woods, R.J. Cotter, J.M. Tuohy, G.A. Krafft, B.S. Bonnell and M.R. Emmerling, Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease, J Biol Chem 271 (1996), 20631-20635.
19. N.S. Schoonenboom, C. Mulder, H. Vanderstichele, E.J. Van Elk, A. Kok, G.J. Van Kamp, P. Scheltens and M.A. Blankenstein, Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice, Clin Chem 51 (2005), 189-195.
20. C. Stenh, H. Englund, A. Lord, A.S. Johansson, C.G. Almeida, P. Gellerfors, P. Greengard, G.K. Gouras, L. Lannfelt and L.N. Nilsson, Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay, Ann Neurol 58 (2005), 147-150.
21. C. Vigo-Pelfrey, D. Lee, P. Keim, I. Lieberburg and D.B. Schenk, Characterization of beta-amyloid peptide from human cerebrospinal fluid, J Neurochem 611 (1993), 1965-1968.
22. D.M. Walsh, I. Klyubin, J.V. Fadeeva, W.K. Cullen, R. Anwyl, M.S. Wolfe, M.J. Rowan and D.J. Selkoe, Naturally secreted oligomers of amyloid beta protein potently inhibit hip pocampal long-term potentiation in vivo, Nature 416 (2002), 535-539.
23. D.M. Walsh, B.P. Tseng, R.E. Rydel, M.B. Podlisny and D.J. Selkoe, The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain, Biochemistry 39 (2000) 10831-10839.
24. J. Wiltfang, H. Esselmann, P. Cupers, M. Neumann, H. Kretzschmar, M. Beyermann, D. Schleuder, H. Jahn, E. Ruther, J. Kornhuber, W. Annaert, B. De Strooper and P. Saftig, Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells, J Biol Chem 276 (2001), 42645-42657.